Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) — specifically, the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus that substantially extends its stability relative to native GHRH. It was developed by Theratechnologies and received FDA approval in 2010 as Egrifta for excess visceral abdominal fat in adults with HIV-associated lipodystrophy — making it one of the few GHRH-class peptides to complete the full regulatory pathway from preclinical development through Phase III trials and approval.
The research base for tesamorelin is therefore unusually deep for a peptide in this class: controlled, randomised Phase III trial data exists, published in peer-reviewed literature with objective endpoints. The mechanistic questions tesamorelin raises — about the GH axis in metabolic disease, the role of visceral adiposity in cardiometabolic risk, and the emerging GH-cognition interface — extend well beyond its approved indication.
01 — GHRH Receptor Pharmacology
Tesamorelin binds the GHRH receptor (GHRHR) on pituitary somatotrophs. Like native GHRH, it activates the Gs/cAMP/PKA intracellular signalling pathway, stimulating both the synthesis and pulsatile secretion of growth hormone. The trans-3-hexenoic acid modification protects the N-terminus from dipeptidyl peptidase IV (DPP-IV) degradation — the primary route of native GHRH inactivation — extending the half-life to approximately 30–40 minutes versus the 2–5 minutes of unmodified GHRH.
Critically, tesamorelin preserves the pulsatile pattern of GH secretion. This is pharmacologically distinct from exogenous recombinant GH administration, which produces supraphysiological, non-pulsatile GH elevation. Tesamorelin acts through the natural regulatory mechanism — stimulating the pituitary to release GH according to its own somatostatin-modulated rhythm — with the attendant negative feedback systems remaining intact.
The result is elevation of mean GH and IGF-1 levels within the physiological range, without the feedback suppression of endogenous GH release that accompanies direct GH administration.
02 — HIV-Associated Lipodystrophy: The Phase III Data
The pivotal trials establishing tesamorelin's approved indication were two randomised, placebo-controlled Phase III studies published by Falutz et al. in the New England Journal of Medicine (2010) and AIDS (2010).
The primary endpoint was change in visceral adipose tissue (VAT), measured by CT scan at 26 weeks. Key findings across both trials:
VAT reduction: Tesamorelin produced a mean reduction of approximately 15–18% in VAT, versus a 2–5% increase in the placebo arm — a statistically and clinically significant difference
IGF-1 elevation: IGF-1 levels increased substantially in the treatment arm — pharmacodynamic confirmation that the GH axis was being appropriately engaged
Triglyceride reduction: Reduced fasting triglycerides were documented as a secondary finding, consistent with the metabolic effects of GH-axis activation on hepatic lipid handling
Reversibility: VAT and IGF-1 changes reversed after treatment cessation — consistent with the mechanism operating through pituitary stimulation rather than permanent tissue modification
The patient population had documented HIV infection and antiretroviral therapy (ART)-associated lipodystrophy — a specific pathological context in which GH axis dysregulation is a documented contributor to visceral fat accumulation.
03 — GH Axis and Visceral Adiposity
The mechanistic connection between GHRH stimulation and visceral fat reduction runs through the GH → IGF-1 axis.
Growth hormone promotes lipolysis — the mobilisation of fatty acids from adipose tissue. Visceral adipose demonstrates higher GH receptor density than subcutaneous depots and is therefore more sensitive to GH-driven lipolysis. In states of relative GH deficiency — documented in HIV-positive patients on ART, in ageing, and in obesity — visceral adipose accumulates preferentially.
IGF-1 mediates many of GH's downstream anabolic effects: protein synthesis, glucose uptake in muscle, inhibition of apoptosis in various cell types. The IGF-1 elevation documented in tesamorelin trials serves as both pharmacodynamic confirmation of GH axis engagement and a potential independent contributor to lean mass effects observed in treated subjects.
Tesamorelin does not directly cause fat loss. It restores a GH pulsatile stimulus that is attenuated in the populations studied, and the downstream metabolic consequences of that restoration include preferential visceral fat mobilisation.
04 — Cognitive Research: An Emerging Direction
Beyond the metabolic indication, a separate body of tesamorelin research has examined the GH/IGF-1 axis in the context of brain function and cognitive ageing.
Baker et al. published findings from a randomised trial in adults with mild cognitive impairment (MCI) and healthy older controls, demonstrating improvements in a composite cognitive score — particularly in executive function and verbal memory — in the tesamorelin arm versus placebo. The proposed mechanism involves GH/IGF-1 signalling in the brain: IGF-1 receptors are expressed in hippocampal and prefrontal regions relevant to memory and executive function, and GH axis decline in ageing is hypothesised to contribute to cognitive trajectory in susceptible individuals.
This research is earlier-stage than the metabolic data — individual trials rather than a Phase III programme — but represents a distinct research vector that has generated substantial interest in tesamorelin beyond its approved indication. Subsequent trials have examined tesamorelin in age-related GH decline specifically, with registered studies ongoing.
Tesamorelin occupies a distinct mechanistic position among GH-axis compounds. Unlike GHRP-class compounds (GHRP-6, GHRP-2, ipamorelin) which act on the ghrelin receptor (GHS-R1a), tesamorelin acts directly on the GHRH receptor — the same target as CJC-1295 No DAC, but with a longer native sequence (44 amino acids versus 29 in CJC-1295 No DAC) and a different stabilising modification.
The combination of GHRHR agonism (tesamorelin, CJC-1295 class) and GHS-R1a agonism (ipamorelin, GHRP class) produces synergistic GH release — both receptor classes act through independent intracellular pathways converging on somatotroph GH secretion. See CJC-1295 No DAC and Ipamorelin: The Mechanistic Case for Combination → for the published synergy data.
For tesamorelin's specific place in the literature, the distinguishing feature is the presence of controlled Phase III trial data — a level of evidence that does not exist for CJC-1295 or most other GHRH-class peptides studied in research contexts.
